The rationale for the project rests on well-recognized shortcomings of current vaccination strategies against lumpy skin disease. Live-attenuated vaccines, while capable of inducing robust immunity, carry lingering safety concerns, particularly in settings where incomplete viral attenuation or reversion could pose risks to herds. Inactivated vaccines, by contrast, tend to deliver incomplete protection and often require repeated dosing. Perhaps most importantly for disease-control programs, neither approach is readily compatible with DIVA-based surveillance, the differentiation of infected from vaccinated animals, which is a cornerstone of modern eradication campaigns. A subunit vaccine containing only carefully selected viral epitopes would, in principle, allow serological assays to distinguish vaccinated animals from naturally infected ones, restoring a critical tool for trade and surveillance authorities.

To build such a candidate, the team turned to an integrated immunoinformatics workflow, a pipeline that mines viral protein sequences for short peptide segments, or epitopes, that the immune system can recognize. The researchers focused on the envelope protein P32 and the surface protein A27L of lumpy skin disease virus, two antigens exposed on the viral surface and therefore attractive targets for neutralizing antibodies and cellular immunity. Using prediction algorithms, they identified candidate cytotoxic T-lymphocyte epitopes, helper T-lymphocyte epitopes and B-cell epitopes from these proteins, and then subjected every candidate to a demanding series of filters. Only epitopes that scored well for antigenicity, showed no allergenic or toxic signatures, did not resemble host proteins in ways that could trigger autoimmunity, and were conserved across viral sequences survived the screening process.

The surviving epitopes were then assembled into a single chimeric construct, stitched together with optimized peptide linkers and augmented with an RS09 adjuvant, a Toll-like receptor agonist designed to sharpen the immune response. The final architecture incorporated two cytotoxic T-lymphocyte epitopes, two helper T-lymphocyte epitopes and two B-cell epitopes. Quantitative assessment of the resulting protein suggested a favorable biochemical profile: an antigenicity score of 0.90, indicating a strong likelihood of provoking an immune response; an instability index of 24.32, well below the threshold that would suggest chemical instability; and a solubility score of 0.87, hinting that the protein could be produced in soluble form during recombinant expression. No allergenic or toxic motifs were detected in the assembled sequence.

Because a vaccine’s amino acid sequence alone says little about its three-dimensional shape, the team next modeled and validated the construct’s structure. Structural quality checks returned an ERRAT score of 99 percent, a measure of overall non-bonded interaction quality in the model, and more than 91 percent of residues fell within favored regions of the Ramachandran plot, the standard gauge of stereochemical plausibility for protein backbone conformations. These metrics indicate a high-quality structural model, providing a credible basis for the downstream interaction studies that followed.

A central question for any adjuvanted subunit vaccine is whether the immune system will actually take notice. The RS09 adjuvant works by engaging Toll-like receptors, and the researchers used molecular docking to test how strongly the vaccine construct binds to bovine Toll-like receptor 9, the relevant innate immune sensor in cattle. The interaction proved to be the strongest among the receptors examined, with a binding free energy of minus 16.2 kilocalories per mole and a predicted dissociation constant of 3.5 times ten to the power of minus twelve, an extraordinarily tight affinity. To confirm that this docking pose was not a fleeting computational artifact, the team ran molecular dynamics simulations lasting 100 nanoseconds, which showed the complex remaining stable throughout, suggesting the interaction could plausibly persist long enough in a real cellular environment to trigger innate immune signaling.

Immune simulation extended the picture to the adaptive arm of immunity. The computational models predicted strong humoral and cellular responses following immunization, characterized by elevated levels of immunoglobulin M, immunoglobulin G1 and immunoglobulin G2, alongside the cytokines interferon-gamma and interleukin-2. That cytokine signature is consistent with a Th1-biased immune profile, the type of response generally associated with robust antiviral defense and effective cytotoxic T-lymphocyte activity. For a virus like lumpy skin disease, where both neutralizing antibodies and cellular killing of infected cells matter, a vaccine that can plausibly elicit both arms of the adaptive response is an encouraging design outcome, even if the predictions remain computational rather than experimental at this stage.

What distinguishes this study from many purely in silico vaccine papers is the step toward experimental feasibility. The researchers codon-optimized the vaccine sequence for bacterial expression and performed in silico cloning to confirm the construct could be accommodated in an expression vector. They then produced the recombinant protein in the laboratory and verified its expression by SDS-PAGE and Western blot analysis, both of which revealed a distinct band at approximately 14.3 kilodaltons, matching the predicted molecular weight of the designed construct. That single band provides tangible, if preliminary, support that the computational design can be translated into a real protein, a hurdle where many multi-epitope candidates have faltered.

The authors are careful to frame the work as a rationally designed and experimentally supported candidate rather than a finished vaccine. No animal immunization or challenge data are presented, and the immune simulations, however detailed, remain predictions that must be tested in cattle or suitable animal models. Nonetheless, the study establishes what the authors describe as a promising platform for safer, targeted and potentially DIVA-compatible next-generation capripoxvirus vaccines. Because the construct contains only defined epitopes from P32 and A27L, companion diagnostic assays could in principle be developed to distinguish vaccinated animals from infected ones, addressing one of the most persistent obstacles to controlling this economically damaging disease.

The broader significance of the work lies in its demonstration of a fully integrated pipeline, from epitope prediction and filtering through structural modeling, receptor docking, dynamics simulation, immune simulation and finally recombinant expression. As transboundary livestock diseases continue to threaten food security and international trade, such computational-first approaches offer a way to move from viral genome to testable vaccine candidate in a fraction of the time required by traditional empirical methods. The research was supported by funding from the National Natural Science Foundation of China, the National Key R&D Program of China and the Shenzhen Medical Research Funds, among other sources, and the article is available open access under a Creative Commons license.

Subject of Research: Immunoinformatics-guided design of a multi-epitope subunit vaccine candidate against lumpy skin disease virus

Article Title: Integrated immunoinformatics-guided development and validation of an immunodominant multi-epitope vaccine candidate against lumpy skin disease virus

Article References: Farrukh, M., Munawar, A., Hussain, N., Pan, F., & Riaz, F. (2026). Integrated immunoinformatics-guided development and validation of an immunodominant multi-epitope vaccine candidate against lumpy skin disease virus. Virology Journal. https://doi.org/10.1186/s12985-026-03326-8

Image Credits: AI Generated

DOI: 10.1186/s12985-026-03326-8

Keywords: lumpy skin disease virus, immunoinformatics, multi-epitope vaccine, Capripoxvirus, P32 protein, A27L protein, RS09 adjuvant, TLR9, molecular dynamics, Th1 immune response, DIVA-compatible vaccines, livestock vaccinology